Follows people with neurologic conditions using the EXOPULSE suit over time
Records outcomes of people with neurologic conditions who use the EXOPULSE suit.
Plain-language title generated from the registry record
Registry title: The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes
Key facts
- Where
- Bergshamra, SwedenSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with cerebral palsy, multiple sclerosis, stroke, fibromyalgia or another neurologic disorder with similar symptoms. They will use the EXOPULSE Mollii Suit or EXOPULSE Suit.
- Age
- 2 years or older
- Sex
- All sexes can join
- Disease stage
- Diagnosed more than 6 months before joining for multiple sclerosis or stroke. Diagnosed more than 1 month before joining for fibromyalgia.
- Earlier treatment
- Cannot have used botulinum toxin less than 3 months before the study or during it. No new medicine affecting nerve and muscle activity during the study.
Main reasons for not taking part
- Any contraindication listed in the instructions for use of the suits
- A new medicine affecting nerve and muscle activity during the study
- Botulinum toxin less than 3 months before or during the study
- Height under 100 cm (3 ft 3 in) and weight under 13 kg (29 lb)
- Height over 205 cm (6 ft 9 in) and weight over 115 kg (254 lb)
Read by machine on 12 November 2026.
Where in Sweden
- Ottobock Care SverigeBergshamra, SwedenContact: Ines CunhaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Otto Bock Healthcare Products GmbH
- Trial code
- NCT05901259
- Record updated
- 14 September 2026
- Original description
The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of symptoms, and to identify high responders among the sub-categories of the diagnoses. The primary endpoint will be improvements in the Berg/Pediatric Balance Scale (BBS/PBS) as a measurement of balance and risk of falls.Read full original descriptionShow less
The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes
The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of symptoms, and to identify high responders among the sub-categories of the diagnoses. The primary endpoint will be improvements in the Berg/Pediatric Balance Scale (BBS/PBS) as a measurement of balance and risk of falls.
Inclusion: Diagnosed with CP, MS, stroke, fibromyalgia or other neurologic disorder that may cause such type of symptoms; Diagnosed >6 months prior to inclusion in case of MS or stroke as well as >1 month prior to inclusion in the case of fibromyalgia; Give written informed consent; Cognitively able to understand and follow verbal and/or written instructions; A minimum age of 2 years.
Exclusion: Being introduced to any new medication affecting the neuromuscular activity during the study period; Using botulinum toxin <3 month before or during the study period; Any of the contraindications listed in the instructions for use of the EXOPULSE Mollii Suit or EXOPULSE Suit; Subjects <100 cm and <13 kg; Subjects >205 cm and >115 kg.